One major breakthrough in cancer immunotherapy has been the identification of immune checkpoint molecules in tumors, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the programmed cell death-1 (PD-1), and its ligands programmed death-ligand 1 (PD-L1) and PD-L2 [58]. This evidence concerns the gene CD274 and cancer.